Peter,
That is indeed interesting. In terms of time before they would hit the US market, is it fair to rank them in the order NBIX, SEPR, NRGN? The rationale is that NBIX is already in pivotal trials, SEPR is going to start such and NRGN is probably a little ways off.
By the way, I have Sonata and it works. Sort of. But you're right, it doesn't last long. Moreover, I think Sonata more or less guarantees only a few hours sleep. At least that is how it works for me. I have Ambien too and that works longer, but the after effects are not so great. Most of the time, I find that a low dose of a benzodiazepene is preferable.
Supposedly, the Neurocrine drug combines the best of Sonata and Ambien. I'm looking for evidence of rebound, but I believe that is absent. I'm going to look at what I can find on the Sepracor candidate.
What one should also look at is the relative significance to each of the companies. Is it comparable or is Sepracor sufficiently big that the effect is more muted? I do not know the answer.....
Thanks, Torben |
